Matinas Biopharma (NYSEAMERICAN:MTNB) Shares Down 3.7% – What’s Next?

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) dropped 3.7% during mid-day trading on Monday . The company traded as low as $0.5265 and last traded at $0.54. Approximately 41,451 shares traded hands during mid-day trading, an increase of 23% from the average daily volume of 33,766 shares. The stock had previously closed at $0.5610.

Matinas Biopharma Stock Performance

The stock’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $0.69. The company has a market cap of $4.09 million, a P/E ratio of -0.32 and a beta of 1.61.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by institutional investors and hedge funds.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.